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Abstract
In several medical decision-making problems, such as antibiotic prescription, labo-
ratory testing can provide precise indications for how a patient will respond to different
treatment options. This enables us to “fully observe” all potential treatment outcomes,
but while present in historical data, these results are infeasible to produce in real-time
at the point of the initial treatment decision. Moreover, treatment policies in these set-
tings often need to trade off between multiple competing objectives, such as effectiveness
of treatment and harmful side effects.
We present, compare, and evaluate three approaches for learning individualized
treatment policies in this setting: First, we consider two indirect approaches, which
use predictive models of treatment response to construct policies optimal for different
trade-offs between objectives. Second, we consider a direct approach that constructs
such a set of policies without any intermediate models of outcomes. Using a medical
dataset of Urinary Tract Infection (UTI) patients, we show that all approaches are able
to find policies that achieve strictly better performance on all outcomes than clinicians,
while also trading off between different objectives as desired. We demonstrate addi-
tional benefits of the direct approach, including flexibly incorporating other goals such
as deferral to physicians on simple cases.
1 Introduction
Many medical treatment settings involve time-intensive or expensive laboratory testing
that provide information about patient responses to all treatments of interest, but which
are unavailable to doctors when they must first make a treatment decision. For instance,
in antibiotic prescription, patients are tested for resistance to several antibiotics, not just
those used for treatment, providing us with information about their response to all relevant
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treatments. However, these results take days to obtain, and doctors have to make an
immediate treatment decision in the meantime.
A similar setting arises in cancer treatment. In patient-derived xenografts (PDX) mod-
els, a patient’s tumor tissue is implanted in a mouse, where its response to various cancer
treatments can be recorded. Moreover, these models take 2-8 months to develop, so physi-
cians typically need to start patients on treatment without knowing the optimal choice
(Wang and Shi, 2019).
Treatment decisions in many medical settings also require doctors to make trade-offs
between competing objectives. For instance, a doctor might aim to maximize treatment
effectiveness while constraining the risk of adverse side-effects to the patient or overall
treatment cost. In the case of antibiotic prescription, doctors have to make a trade-off
between the objectives of treatment effectiveness and minimizing usage of 2nd line, or
broad spectrum, antibiotics. Broad spectrum antibiotics have a higher likelihood of being
effective, but overuse leads to increased population-level resistance rates in the long run.
In this setting, the objective is to maximize antibiotic effectiveness while limiting usage of
2nd line antibiotics.
In this work, we present methods for learning treatment policies in such multi-objective
settings with fully observed outcomes for the treatments of interest. We present both
indirect and direct policy learning approaches for learning a set of treatment policies that
exhibit various trade-offs between the objectives. We then apply these methods to learn
policies for making antibiotic prescription decisions in patients with urinary tract infections
(UTIs). Our primary contributions in this work are as follows:
• We present three treatment policy learning methods for settings with fully observed
outcomes and multiple objectives, and highlight the trade-offs across the various ap-
proaches.
• Using a clinical dataset of Urinary Tract Infection (UTI) patients, we show that all
methods are able to significantly exceed clinician performance with respect to multiple
important treatment objectives.
• We show that our methods are able to learn a set of policies that can effectively trade
off between treatment objectives, enabling practitioners can select a policy with the
desired trade-off at decision time.
• We use a synthetic environment to demonstrate that direct policy learning learns
superior treatment policies relative to indirect approaches in settings with complex
outcome models, but simple optimal treatment rules.
• We show that the direct learning framework naturally accommodates other consider-
ations, such as deferral to clinician decisions in situations where physicians typically
perform well. We demonstrate this use case in the antibiotic prescription setting as
well.
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2 Related Work
There are several related areas of research that deal with learning policies from retrospective
data of contexts, actions, and outcomes, and we outline some connections here. Several
lines of research focus on the setting where the only observed outcome corresponds to the
action that was taken. In the contextual bandits literature, this is referred to as bandit
feedback, and the retrospective setting is referred to as the “batch” setting (Swaminathan
and Joachims, 2015). In biostatistics, epidemiology, and causal inference more broadly, the
outcomes are referred to as “potential” or “counterfactual” outcomes (Imbens and Rubin,
2015; Hernan and Robbins, 2020) and the fact that we only observe a single outcome per
individual is referred to as the fundamental problem of causal inference.
Within epidemiology and biostatistics, a policy is sometimes referred to as an individu-
alized treatment rule (ITRs), and two broad approaches exist to learning them, an indirect
and a direct approach. In the indirect approach, the conditional distribution of the out-
come (given patient characteristics) for each action is modeled directly, and a decision rule
is obtained by choosing the action that maximizes the outcome of interest. This includes
approaches such as Q-learning, A-learning, and regret regression (Nahum-Shani et al., 2012;
Schulte et al., 2014; Henderson et al., 2010) However, the model class of the resulting ITR is
dependent on the model class used for the conditional outcomes: If a linear ITR is desired,
then it necessitates the use of a linear model class for the conditional outcome models.
In cases where a simple outcome model does not accurately capture the true conditional
outcome function, the learned ITR may be sub-optimal (Min and Murphy, 2011). By con-
trast, the direct approach develops an estimator of the expected conditional outcome as a
function of a decision rule, and directly optimize the value of this estimator by searching
over the space of treatment decision rules. This removes the dependence between the com-
plexity of the learned ITR and the outcome models to avoid misspecification. For problems
with binary treatments, this direct optimization problem is equivalent to weighted binary
classification, and is referred to as outcome weighted learning (Zhao et al., 2012). Recent
work has also focused on developing and analyzing convex surrogates for this problem to
allow for efficient optimization of the objective (Zhao et al., 2019) and extend this to the
multi-action setting (Huang et al., 2019).
In our setting, we have access to counterfactual outcomes of all possible treatments.
Thus, a close setting to ours is that of cost-sensitive multi-class classification (Elkan, 2001),
where the true loss function is the multi-class equivalent of a weighted 0-1 loss in binary
classification. In this setting, smooth convex surrogates for this objective are used for
learning (Zou et al., 2008), with the desideratum that they are consistent for the Bayes
optimal classifier (Zhang, 2004; Tewari and Bartlett, 2007), and Huang et al. (2019) use
the same multinomial deviance risk that we use as our direct policy learning approach. All
of these cases, as well as our own, are concerned with deterministic policies, because these
are generally optimal for cases where exploration is not required (and stochastic policies
introduce further optimization difficulties, as studied in the bandits literature (Chen et al.,
2019)).
Multi-objective decision-making has been long-studied in the context of single decisions
(Zeleny and Cochrane, 1982; Vira and Haimes, 1983) and recently in the context of sequen-
tial decision-making, typically formulated as a Markov Decision Process with a vector-valued
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objective (Roijers et al., 2013) and a scalarization function (to convert the vector-valued
objective into a scalar reward) that is unknown at train-time, but often assumed to be a
linear combination (Natarajan and Tadepalli, 2005). Many of these methods seek to main-
tain a set of policies that are optimal for different linear scalarization functions (Natarajan
and Tadepalli, 2005; Barrett and Narayanan, 2008; Lizotte et al., 2012), and can be seen as
indirect methods in their use of Q-functions to do so. The set of objective values achieved
by the set of optimal policies (each optimal for a different possible scalarization function) is
known as the Pareto frontier (Yang et al., 2019). Our indirect approach of expected reward
maximization can be seen as roughly the one-step (and therefore much simpler) equivalent
of some of these methods. Our direct approach borrows (albeit more conceptually) from
these methods as well, in that we learn a set of policies corresponding to a set of fixed linear
preferences.
In our specific application area of antibiotic prescription in urinary tract infections,
recent work (Yelin et al., 2019) learned treatment policies in a setting with fully observed
outcomes, but with the single objective of maximizing treatment effectiveness. They used an
indirect approach, training models to predict resistance and selecting the antibiotic with the
minimum predicted resistance probability. Their work did not address the multi-objective
nature of the antibiotic prescription problem. Another recent paper (Oonsivilai et al., 2018)
develops models for predicting resistance to a single antibiotic using a utility-based objective
that accounts for factors beyond treatment effectiveness, such as drug cost. However, they
do not address how these resistance predictions or their proposed utility-based framework
could be used to construct a treatment policy that selects among several antibiotics.
3 Policy Learning Methods
3.1 Overview
In the general formulation of the multi-objective policy learning problem, we let A = [K]
denote the action space, where K is the number of discrete actions, we denote features as
X ∈ Rm, and we will seek to choose a policy pi : Rm → A which maps from features (i.e.,
patient characteristics) to recommended actions. Note that we use bold-faced symbols like
X to denote vectors, and X(i) to denote the i-th entry of a vector.
In our particular setting, we will focus on optimizing over two objectives, and will adapt
our notation accordingly. Our dataset is of the form {(Xi,Yi,Ci)}ni=1, where Xi ∈ Rm
are patient features, and Yi,Ci represent our competing objectives, a benefit and a cost
respectively. In the antibiotic prescription setting, Yi ∈ {0, 1}K , where Y (a) is an indicator
for whether antibiotic a is effective in treating an infection, and Ci ∈ {0, 1}, where C(a)
is an indicator for whether the chosen antibiotic is broad-spectrum, whose use we wish to
minimize in the interests of avoiding population-level antibiotic resistance. We make two
remarks: First, broad-spectrum antibiotics tend to be more effective in expectation, leading
to a trade-off between these two objectives. Second, we observe outcomes for all treatments
/ actions, not just the one received by a patient, as our dataset contains laboratory results
that indicate the susceptibility of the infection to different drugs.
We present three approaches in this section. Each approach will seek to return a set
of policies Π, where each element pi ∈ Π represents an optimal policy for some trade-off
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between Y and C. The first two methods can be viewed as indirect approaches, in that
they require learning a separate model for the conditional mean of Y under each treatment1,
denoted fa(x) ≈ E(Y(a) | X = x). The third approach is a direct approach, in that it does
not require predictive models for the individual outcomes, but optimizes directly for a
treatment policy. To summarize these approaches:
1. Thresholding: Use a set of carefully-chosen thresholds to convert fa(x) into a binary
prediction of effectiveness Y (a) for each treatment, and then choose the lowest-cost
treatment which is predicted to be effective.
2. Expected Reward Maximization: Combine Y and C into a single objective rω
(the “reward”) by taking linear combinations with varying weights, and choose the
treatment which maximizes this reward according to the models fa(x).
3. Direct Policy Optimization: Using the same definition of reward rω, learn a single
model that directly predicts which treatment is optimal by optimizing a surrogate
loss.
3.2 Thresholding
In this section, we introduce a simple method whose decision logic is intuitive: Predict which
treatments will be effective, and then choose the effective treatment with the lowest cost.
Given our learned models fa(x) of predicted effectiveness, which output numbers between
0 and 1, we use carefully-chosen thresholds to make a binary prediction for each Y (a). We
combine these predictions with the fixed cost associated with broad-spectrum antibiotics to
choose the lowest-cost treatment that is still predicted to be effective.
More formally, we denote the set of thresholds used to binarize each prediction as
{ta}Ka=1. We let ea(x) be an indicator2 that represents whether treatment a is predicted to
be effective for patient with features x, given by
ea(x) = 1 [fa(x) ≥ ta]
The treatment policy is then defined as the action that minimizes cost, among the treat-
ments that are predicted to be effective
pi(x) = arg min
a
{c(a) | ea(x) = 1}
In the event where ea(x) = 0 for all a ∈ A, the treatment policy falls back to an option a
that minimizes the cost c(a). In our setting, this corresponds to defaulting to a first-line
antibiotic.
Choosing thresholds: A single set of thresholds implicitly defines a policy with a
fixed trade-off between effectiveness and other costs. To construct a set of policies Π that
1In our case, costs are determined by the choice of treatment itself, so we only need to model the
conditional mean of treatment effectiveness, but it is straightforward to extend both methods to the case
where all objectives must be modelled.
2Throughout, we use 1 [P ] as an indicator function that is equal to 1 if the expression P is true, and 0 if
P is false
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express varying preferences between treatment effectiveness and other costs, we perform an
exhaustive search over different choices of threshold combinations {ta}Ka=1 ∈ T , where T is
a large (but finite) search space.
Each policy pi implied by our models fa and thresholds ta is then evaluated on a held-
out validation set to get an empirical estimate of their expected benefit E[Y (pi(x))] and
expected cost E[C(pi(x))]. We then enumerate over a set of cost constraints {bj}Jj=1, and
return the J policies which satisfy
pi∗ = arg max
pi
{E[Y (pi(x))] : E[C(pi(x))] ≤ bj}
In other words, we choose the policy for each bj which achieves the highest mean value of
Y in our validation set, subject to the constraint that the mean cost is less than bj .
This approach, while straightforward and interpretable, does have drawbacks. It requires
enumeration over a large set of thresholds T , and thresholding predicted probabilities throws
away information: For instance, two treatments with equal cost could both have predicted
probabilities of effectiveness greater than their respective thresholds, but where the model
is far more confident in one over the other. In the next section, we present a method
that circumvents these issues, while making the trade-off that the resulting decision logic
(maximizing an expected reward) may be less interpretable to a lay audience.
3.3 Expected Reward Maximization
In a single objective setting, a simple approach for converting predictions of treatment
effectiveness into a policy for a patient with features x would be to select the treatment
a∗ = arg maxa fa(x), i.e., choose the treatment that is most likely to work, based on our
model predictions.
In our setting we have multiple objectives, but if we combine our objectives into a single
number indicating a notion of value or reward, then we can construct a similar policy that
optimizes this quantity.
More formally, recall that our goal is to learn a deterministic treatment policy pi : Rm →
A, which maps patient features to a deterministic decision. To combine our objectives, we
will use a linear preference parameter ω ∈ [0, 1] such that the reward is linear combination
of our competing objectives. In our particular case, we parameterize this as follows, to
account for the fact the our cost is a binary variable
rω = ω ·Y + (1− ω) · (1−C), (1)
where rω(a) represents the reward under treatment a. We will omit the subscript where it
is clear from context.
In the setting of linear preferences, commonly used in the multi-objective optimization
literature (Stewart, 1992; Natarajan and Tadepalli, 2005) we do not lose anything by re-
stricting ourselves to deterministic policies, because there exists an optimal policy that is
deterministic (Roijers et al., 2013). Under this preference ω, we define the Bayes optimal
policy pi∗ω as the one that maximizes the expected reward for a given x, and is defined with
respect to the true (unknown) conditional expectations
pi∗ω(x) = arg max
a∈A
E[rω(a) | x] (2)
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In the setting we consider, we adopt a strategy of learning a set of policies Π that are each
optimal according to some preference ω, allowing users to select a policy from this set which
corresponds to their desired trade-off. This is referred to as the “decision support” setting
(Roijers et al., 2013) in that we do not solicit an explicit preference ω from decision makers,
but instead provide a set of alternatives that are each optimal for some ω.
Using this formalism and the definition of reward in Equation (1), we can use our models
fa(x), which approximate E[Y (a)|X = x], to construct a prediction of this reward under
each action a, and then define our treatment policy piω(x) as the one that chooses the action
with the highest predicted reward
piω(x) = arg max
a
ωfa(x) + (1− ω) · (1− C(a))
Constructing such a decision rule for each ω produces our desired set of policies Π. This
approach has the benefit of not requiring enumeration over a large set of thresholds, and it
takes the predicted probabilities into account directly.
However, this approach requires us to build predictive models of treatment effectiveness,
and can introduce a trade-off between policy performance and interpretability. For instance,
representing the outcome models fa with linear functions allows us to interpret the learned
policy and gain insight into features driving decisions by examining differences in coefficients
3. In many settings, linear models may be too simple to accurately model outcomes, which
can lead to poor performing models (and therefore policies). On the other hand, more
complex models sacrifice the interpretability of the resulting policy. In the next section,
we present a method which instead seeks to find a policy of the desired model class (e.g.,
linear) directly.
3.4 Direct Policy Optimization
In this approach, we seek to directly learn a policy which has an interpretable form, without
learning any specific models of treatment effectiveness. We will use the same notion of
reward defined in Section 3.3, and will optimize the (estimated) value of a treatment policy
pi, Vˆω(pi). As before, we learn a range of policies corresponding to different values of ω.
In this case, our objective is to find a function pi : Rm → A which maximizes the following
objective, and we note that any such policy can be written as pi(x) = arg maxa∈A d(x, a)
for some function d : Rm ×A → R, leading to the formulation
pi∗ω = arg max
pi
Vω(pi) := Ex,r
[∑
a∈A
rω(a)1 [a = pi(x)]
]
= Ex,r
[∑
a∈A
rω(a)1
[
a = arg max
a∈A
d(x, a)
]]
We will omit ω in the remainder of this section, as we will choose a finite set of values for
ω to generate a set of optimal policies piω for each.
3If there are two actions, then this is a direct consequence of the formulation, and for more than two
actions the policy can be interpreted as a set of linear classifiers by comparing the difference in coefficients
for models of pairs of treatments
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To find an optimal policy, we wish to optimize over the space of decision functions d
using the empirical estimate of V (pi), but the argmax operation causes this objective to be
non-convex. Instead, we will use a differentiable convex surrogate objective (Tewari and
Bartlett, 2007; Zou et al., 2008), in our case the multinomial deviance loss (Zou et al.,
2008; Huang et al., 2019), which has the appealing property that it is not only convex
and differentiable, but that when solved to optimality it yields a consistent estimator of
the Bayes-optimal policy. Concretely, we optimize over functions fa : Rm → R, where our
resulting policy will be given by pi(x) = arg maxa fa(x), and seek to minimize the following
quantity in our empirical sample
Ex,rL˜(f, x, r) := −E
[∑
a∈A
r(a) log
exp fa(x)∑
a′ exp fa′(x)
]
(3)
In this work, we parameterize the functions fa with a linear model, such that fa(x) = θ
T
a x.
As noted, this objective has the appealing property that, when solved to optimality, it will
yield a policy that is consistent for the Bayes-optimal policy in the following sense (proof
provided in the appendix)
Proposition 1. For nonnegative rewards r, and for an f∗ that satisfies f∗ = inff Ex,rL˜(f, x, r),
the corresponding policy pi∗(x) = arg maxa f∗a (x) is equivalent to the the Bayes-optimal pol-
icy pi∗(x) = arg maxa E[r(a)|X]
Directly optimizing for a treatment policy in this way decouples the complexity of the
outcome models in a given setting from the complexity of an effective treatment policy.
This enables the learning of interpretable decision-making policies even in a setting where
modeling outcomes requires extremely sophisticated models.
4 Experiments
We evaluate each of the three policy learning approaches in the setting of antibiotic pre-
scription for urinary tract infections (UTIs). We begin with some clinical background and
motivation for the problem of antibiotic prescription and some details regarding our clinical
dataset. Our main findings are as follows
1. Improvement in both objectives: All three methods are able to recover policies
that strictly outperform clinicians in both treatment effectiveness and 2nd line usage
rates to a clinically meaningful degree.
2. Variety of policies along the frontier: All three methods recover a variety of
policies that encode different trade-offs between objectives. For instance, all methods
are able to reduce IAT by over 20% relative to clinicians with minor reductions to
2nd-line usage. For other points on the frontier, all methods are able to achieve nearly
zero 2nd-line usage, while still reducing IAT by nearly 10% relative to clinicians.
3. Interpretation of policies: We examine one of the policies learnt by the direct
method, and confirm the factors driving particular treatment decisions are consistent
with clinical intuition.
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We then highlight, through synthetic and real-data experiments, two advantages of the
direct policy learning approach over the other two approaches.
1. Incorporating Deferral: First, we demonstrate how this framework can elegantly
incorporate other desiderata though simple changes to the reward function. For this,
we use the example of deferral to clinician decisions: Through a change in the reward
specification, we encourage the model to defer to clinicians in cases where physicians
tend to perform well. We empirically demonstrate that this works as desired, where
the cases prioritized by the model align with those where physicians perform poorly.
2. Sample Efficiency: We demonstrate through synthetic experiments that when (a)
the Bayes-optimal policy is simple (e.g., linear), but (b) the true conditional outcomes
are complex (e.g., nonlinear), then the direct policy optimization approach can take
advantage of this structure and learn good policies with fewer samples than the indirect
approach of expected reward maximization.
4.1 Background: Antibiotic Resistance
When a patient presents at the hospital with an infection, clinicians typically need to make
an immediate decision on which antibiotic to administer. While laboratory tests can assess
the susceptibility of an infection to each antibiotic, they take time: The bacteria must be
grown in culture to sufficient quantities where the effectiveness of antibiotics can be tested
directly, and this process takes several days to return results.
This is known as the ‘empiric treatment setting’, where doctors must make the initial
prescription decision without the benefit of tests, using the patient’s medical history and
their own clinical experience. They must weigh two competing concerns: Avoiding an
inappropriate antibiotic therapy (IAT) where the pathogen is resistant to the antibiotic,
while also avoiding overuse of broad-spectrum therapies that lead to higher resistance rates
at an individual and population level.
This problem is particularly prevalent in UTIs, a common class of infection with more
than 150 million annual cases worldwide (Stamm and Norrby, 2001). Resistance rates to
commonly prescribed agents in UTIs can exceed 20%, highlighting the difficulty of prescrib-
ing an effective antibiotic (Farrell et al., 2003). Doctors frequently use 2nd-line antibiotics
(Kabbani et al., 2018) because they are more effective at the individual level, but this
contributes to higher prevalence of antibiotic-resistant pathogens in the future at the popu-
lation level. Conversely, 1st-line (narrow spectrum) antibiotics are more likely to be resisted
at an individual level, but pose less risk of increasing population-level resistance.
In practice, this trade-off is difficult to balance. Antibiotic resistance is influenced by a
wide range of risk factors, from individual history of infection to population-level resistance
rates and antibiotic usage trends, which are difficult to incorporate in real time decision-
making. This motivates the need for learning data-driven antibiotic treatment policies that
can make this trade-off in an optimal fashion.
4.2 Data
Our dataset is derived from the electronic health record (EHR) of Massachusetts General
Hospital and the Brigham & Women’s Hospital in Boston, MA, containing the full medical
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record for every patient who has undergone an antibiotic resistance test. This study was
approved by the Institutional Review Board of Massachusetts General Hospital with a
waived requirement for informed consent.
4.2.1 Cohort
Our cohort for this work consisted of 15,806 microbiological specimens collected from 13,682
women with UTIs between 2007 and 2016. We filtered specifically for patients with uncom-
plicated UTI, which refers to an infection in an otherwise healthy female. This excludes
males, pregnant women, or women who had surgical procedures performed in the last 90
days. Patients with uncomplicated UTI typically receive prescriptions from a well-defined
set of antibiotics, allowing us to clearly specify our action space for policy learning and
evaluate performance of learned policies against clinician decisions.
4.2.2 Features
The dataset contains demographics (e.g., age, race), medications (including antibiotic pre-
scriptions), basic lab test results, medical procedures, and comorbidities for each patient.
It also contains information about the date and location that a specimen was collected,
ground-truth antibiotic resistance profiles, and any previous resistance test results or infec-
tions in a patient’s history.
4.2.3 Treatments
Our treatment space consists of common antibiotics used in treating UTIs: nitrofurantoin
(NIT), trimethoprim-sulfamethoxazole (SXT), ciprofloxacin (CIP), and levofloxacin (LVX).
NIT and SXT are 1st-line (narrow spectrum) antibiotics, and CIP and LVX are 2nd-line
(broad spectrum) antibiotics. We filter for uncomplicated UTI specimens that were treated
with exactly one of the four agents in the empiric treatment setting, defined as the period
spanning 2 days before to 1 day after the date of specimen collection. Empiric prescription
information is not used during policy learning, as our goal is not to imitate clinician actions,
but to improve on them. They are solely used to compare the decisions made by our learned
policy to clinician actions. We also filter out specimens missing resistance test results for
any of these four antibiotics, since this information is necessary for a full evaluation of policy
decisions.
4.2.4 Feature Construction
We directly used age, race, and location of specimen collection as features in the model.
We constructed binary features for antibiotic exposure, prior antibiotic resistance, prior
infections, and comorbidities over the 7, 14, 30, 90, and 180-day periods from the specimen
collection date. The values for a feature over each period were included separately in the
model. We also construct a population-level feature called colonization pressure, defined as
the proportion of resistant specimens to a given antibiotic within a specified location and
time window. Finally, we compute the cumulative antibiotic usage rates across all hospitals
in the 90-day window preceding specimen collection, normalized by total patient volume.
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Table 1: Cohort Statistics
Train (2007-13) Test (2014-16)
n 11,865 3,941
Age 34.1 (10.8) 33.6 (11.1)
% White 64.6% 63.0%
% Resistant
NIT 12.3% 11.2%
SXT 19.6% 19.6%
CIP 5.3% 6.4%
LVX 5.1% 6.5%
% Prescribed
NIT 15.9% 34.5%
SXT 41.5% 32.0%
CIP 39.2% 32.5%
LVX 3.3% 1.0%
These last two features are the same for all patients who have specimens collected at the
same location on the same date.
4.2.5 Train / Test Split
Out of the total 15,806 specimens, our training set consisted of 11,865 specimens collected
from 2007-13, and we evaluated the learned policies on a held-out test set consisting of 3,941
specimens from 2014-16. This is after removing any specimens from the test set that came
from patients who were also present in the training set to avoid any data leakage between
train and test sets. Table 1 contains basic statistics about the cohort, including resistance
rates and the distribution of empiric prescriptions in both train and test sets.
4.3 Experiment Setup and Evaluation
Treatment policies were learned using the training set, containing specimens from 2007-13,
and evaluated on the test set, containing specimens from 2014-16. We used data con-
taining specimens from 2012-13 as a validation set for hyperparameter selection across all
approaches.
4.3.1 Thresholding and Expected Reward Maximization
We trained logistic regression models to predict treatment effectiveness for each of the four
antibiotic treatment options: NIT, SXT, CIP, and LVX. Regularization type and strength
were tuned using the validation set. For the thresholding-based approach, the search space
of thresholds T for each model was chosen for a diversity of false-positive rates (for prediction
of susceptibility), using ROC curves on the training set, and T is defined as all possible
combinations of these threshold values.
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Table 2: Policy Comparison: Constant 2nd line usage
IAT 2nd line usage
Doctor 11.9% 33.6%
Thresholding 9.2% 30.6%
Expected reward maximization 9.4% 28.7%
Direct learning 9.4% 30.4%
4.3.2 Direct Policy Optimization
The surrogate loss function (3) was optimized with the Adam optimizer and L2 regular-
ization. The number of training epochs was chosen with an early stopping criteria based
on the mean reward on the validation set. All models were implemented using PyTorch
(Paszke et al., 2019).
4.3.3 Evaluation
We evaluated the learned policies with respect to two primary outcomes: IAT rate and 2nd
line usage. IAT rate is the proportion of antibiotics to which a specimen is resistant, and
2nd line usage is the proportion of antibiotics which are CIP or LVX. We compute clinician
performance and the performance of our policy using the results of the antibiotic resistance
lab test, enabling a head-to-head comparison with our learned treatment policy.
4.4 Reward Function
We now recall the definition of the composite reward function given in Section 3.3 used
for the indirect expected reward maximization and direct policy learning approaches. The
treatment effectiveness vectors Y correspond to a patient’s susceptibility to each antibiotic
Yi(a) = 1 [patient i is susceptible to antibiotic a], the cost vector C for the treatments are
a function of the class of the chosen antibiotic Ci(a) = 1 [a is a 2nd line antibiotic], and the
composite treatment reward is defined as a linear combination of the effectiveness and costs
for each antibiotic using the preference ω ∈ [0, 1], given by ri = ω ·Yi + (1− ω) · (1−Ci).
As ω is reduced, more weight is placed on avoiding 2nd line antibiotic usage, even at the
cost of additional cases of IAT. By varying ω, we can learn a set of treatment policies that
achieve different trade-offs between treatment effectiveness and broad spectrum usage.
4.5 Results
We present the results of learning policies using both the indirect and direct policy learning
approaches outlined in Section 3 for several settings of the cost constraints bj (for the
thresholding approach) and reward weights ω (for the reward maximization and direct
learning approaches). Figure 1 shows the performance of the resulting set of policies for
each approach on the 2014-16 patient cohort with respect to the IAT and 2nd line usage
rates.
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Table 3: Policy Comparison: Improvement in both outcomes
IAT 2nd line usage
Doctor 11.9% 33.6%
Thresholding 10.9% 2.2%
Expected reward maximization 10.9% 0.6%
Direct learning 11.0% 1.3%
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Figure 1: Performance frontier of policies learned with each approach compared to clinician
performance. Y-axis gives the 2nd line usage rate, and the X-axis gives the inappropriate
antibiotic therapy (IAT) rate.
We observe that the sets of policies learned by all three approaches achieve similar
performance for a broad range of IAT and 2nd line usage rates. In the reward maximization
and direct learning approaches, the reward weight ω is able to successfully control the trade-
off learned by the policy. As ω is reduced (i.e, treatment effectiveness is less important),
the policy performance moves down and to the right along the performance frontier shown
in Figure 1.
We compare the performance of our learned policies to that of doctors on the same
patient cohort in Tables 2 and 3. In Table 2, we choose a policy from the policy set
constructed by each method that does no worse than clinicians on 2nd line usage rate, and
compare the corresponding IAT rates. All three approaches reduce the IAT rate by over
20% relative to clinicians, while also producing a minor reduction in the 2nd line usage
rate. In Table 3, we choose a policy from the policy set constructed by each method that
improves both IAT and 2nd line usage rates relative to clinicians. All three approaches are
able to virtually eliminate 2nd line usage while also reducing the IAT rate by nearly 10%
relative to clinicians.
Overall, we find that the frontier of policy performance for all three approaches lies
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Table 4: Top features driving recommendation of NIT over SXT, both 1st-line agents.
Numbers in parentheses correspond to the time window, in days, over which feature was
computed. For instance, “Prior resistance: SXT (180)” is an indicator for resistance in the
past 180 days.
Recommendation of NIT over SXT
Prior resistance: SXT (180)
Prior resistance: SXT (90)
Location A
Prior treatment: folate-inhibitor (7)
Prior treatment: SXT (7)
Location B
Prior treatment: folate-inhibitor (14)
Prior resistance: SXT (30)
Prior treatment: SXT (90)
Prior resistance: GEN (180)
significantly below and to the left of the point representing clinician performance, and we
can achieve significant improvements relative to clinical practice by selecting appropriate
points along the frontier.
4.6 Policy Interpretation
The direct policy learning approach enables interpretation of the learned treatment policy
to understand features important for decision-making. The linear model learns a d × K
weight matrix θ, where each column contains the coefficients used to calculate the output
for a particular antibiotic.
We examine the features important in our policy’s decisions for recommending antibiotic
a over antibiotic a′ by looking at pairwise differences in coefficient values in the correspond-
ing columns of θ. We extract the features i for which θa(i)− θa′(i) is large. We can perform
this comparison for all pairwise combinations of antibiotics in our action space to extract
the features of interest.
In our analysis here, we specifically focus on the factors driving recommendation of NIT
over SXT (both 1st line antibiotics). The populations of patients that are resistant to NIT
and SXT are largely disjoint (i.e, there are many patient resistant to exactly one of these
agents), so accurately deciding when to use one agent over another is crucial for good policy
performance. For a policy trained using a reward function with ω = 0.88, these features are
listed in Table 4.
We find that many of these features align with knowledge that prior resistance or expo-
sure to an antibiotic promotes resistance to that antibiotic in the future. For instance, prior
resistance to SXT is an important factor in driving recommendation of NIT, along with
prior treatment with SXT in the recent past. We note that almost all the features shown
above are features specific to an individual’s personal history of antibiotic exposure and re-
sistance, with the exception of two features for specific hospital locations. Population-level
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Figure 2: Comparison of doctor and algorithm IAT / 2nd line usage on the ‘decision cohort’ -
the subset of examples where the model makes a decision - at different deferral rates. As the
deferral rate increases, the model’s IAT rate remains relatively constant, while the doctor’s
IAT rate increases more sharply. The model learns to take action on the cases where the
clinician exhibits the poorest performance.
statistics related to antibiotic resistance and usage rates, such as colonization pressure or
cumulative antibiotic usage, do not appear to be as useful as patient-specific details when
determining the selection of one 1st-line antibiotic over another.
4.7 Deferring to Doctors
When integrating decision algorithms into medical settings, it is useful to give the algorithm
the option to defer to the clinician’s decision. For instance, one might only want the
algorithm to provide input on cases where the clinician’s decision is particularly likely to
result in ineffective treatment. Designing a system in this way may help doctors avoid
‘alarm fatigue’ from excessive computerized alerts and increases the likelihood that they
will incorporate algorithm input into their decision-making process.
The ability to incorporate deferral in a straightforward manner is a significant advantage
of the direct learning approach. Adding this option in an indirect learning framework would
require us to develop models of clinician behavior to calculate the expected reward of the
doctor making the prescription decision for a given patient, which may be difficult to do. In
this direct approach, incorporating a deferral option is no more difficult than incorporating
an additional antibiotic treatment option. We simply expand our action space to include a
‘defer’ action, and define the reward for this action as:
ri(defer) = ri(a) + λdefer (4)
where a is the action taken by the doctor and λdefer is a positive parameter that controls
the extent to which we incentivize deferral. Adding this ‘deferral reward’ encourages the
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Figure 3: Comparison of indirect and direct policy learning approaches in synthetic setting
learned policy to defer on cases where the doctor takes a reward-maximizing action, and to
make a decision when doctors are likely to make an error.
We examine the learned policy’s performance for a fixed ω and several values of λdefer.
In Figure 2, we compare the IAT and 2nd line usage performance of doctors and the learned
policy on the ‘decision cohort’, the subset of patients where the algorithm makes a decision.
The results are shown for policies learned using a reward function with ω = 0.92 and values
of λdefer in the range [0, 0.05].
On the left plot in Figure 2, we can observe that the gap in IAT rate between doctor
and algorithm performance widens as the policy’s deferral rate is increased (i.e, the decision
cohort shrinks). As the deferral rate increases from 5% to 70%, the gap in IAT rate between
algorithm and doctor on the decision cohort grows from 2.6% to 3.8%, a relative increase
of over 45%. This trend indicates that the learned policy is successfully able to identify the
subset of patients where it can provide the most improvement when constrained to only
take action on a limited number of cases. On the right plot, we also show the 2nd line usage
on the decision cohort for each of these policies. We note that while there is higher variance
in the fluctuations of the 2nd line usage rate as the deferral rate is changed, the range of
observed 2nd line usage is still relatively limited and does not affect the interpretation of
the observed trend in the IAT gap.
4.8 Synthetic Evaluation: Direct vs. Indirect
Even though direct and indirect methods achieved similar performance on our real-world
antibiotic dataset, we demonstrate in this section a scenario where direct policy learning
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can significantly outperform an indirect approach. In particular, this can occur when the
true treatment outcome models are complex, but the optimal treatment rule is simple. For
clarity, we illustrate the benefit of direct learning in a single-objective setting in these syn-
thetic experiments, but an extension to multi-objective settings in the framework discussed
previously is straightforward.
Our environment consists of m-dimensional feature vectors X ∈ Rm and an action space
A with 3 actions. All feature values are drawn i.i.d. from a standard Gaussian distribution.
We use the binary random variable Y (a) to denote the outcome of action a. The values of
each Y (a) for a given X are generated according to the following models:
Y (a) | X ∼ Bernoulli
(
σ
(
Xa +
m∑
i=4
αiX
2
i +
∑
(i,j)∈S
βiXiXj
))
(5)
for a = 1, 2, 3, where αi, βi are coefficients that are fixed across all 3 outcome models and S
is a subset of all distinct pairs of features. These are all nonlinear functions of the features
X, but the Bayes-optimal treatment rule for maximizing under these outcome models is
given by an argmax over linear functions
pi∗(X) = arg max
a∈{1,2,3}
Xa. (6)
We compare the performance of an indirect approach (expected reward maximization) and
the direct policy optimization approaches for policy learning in this environment. In the
indirect approach, we independently train logistic regression models ha to predict the out-
comes Y (a) for each a. The treatment rule is then defined as arg maxa ha(x). In the direct
approach, we optimize the following loss function, where f is parameterized by a linear
model:
L˜(f, x) = −
n∑
i=1
∑
a∈A
1 [Y (a) = 1] log
exp fa(x)∑
a′ exp fa′(x)
(7)
The results are shown in Figure 3. We plot the mean outcome of both approaches on a
held-out test set for various training set sizes. We only compute the mean performance
on the subset of examples in the test set for which outcomes were not uniform across all
3 actions (i.e, not all 0 or 1), as performance on the remaining samples does not depend
on the policy. We also plot the mean performance of the Bayes-optimal policy given in
Equation (6).
We observe that direct policy learning significantly outperforms the indirect approach
across a wide range of training set sizes and rapidly approaches the Bayes-optimal per-
formance with far fewer samples. This synthetic experiment demonstrates that the direct
learning approach, in contrast to the indirect approach, is able to take advantage of scenar-
ios where the optimal treatment policy is simple, even when the true conditional outcome
models are complex.
5 Conclusion
In this work, we presented three approaches for learning treatment policies in clinical set-
tings with multiple treatment objectives and access to retrospective data that provides
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strong indicators for counterfactual treatment outcomes. We applied these approaches for
learning antibiotic treatment policies for UTIs, and found that all our approaches achieved
comparable performance and exceeded clinician performance across multiple treatment ob-
jectives. We also evaluated trade-offs among these approaches, and highlighted some signif-
icant advantages of direct learning in both real-world and synthetic experiments. We note
that if one were in a setting without access to all counterfactual outcomes, one could still
use the methods presented in this work in conjunction with appropriate estimators for the
unobserved treatment outcomes.
Our empirical evaluation provides a real-world example for how to use machine learning
to guide treatment selection. The fully observed setting has important impactful applica-
tions in settings such as antibiotic prescribing and precision medicine using patient-derived
xenograft (PDX) models. At the same time, it is clearly a special case and is much simpler
than the partially observed setting, where one has to simultaneously grapple with coun-
terfactual estimation from biased data. As such, it is an ideal test bed for studying more
subtle aspects of policy learning for guiding treatment selection. In this work, we addressed
two important aspects of making treatment decisions in the real world: handling trade-offs
between multiple objectives and deferring to clinician decisions when appropriate; future
work using this type of data could examine the impact of nonstationarity on policy learning
methods or techniques for developing more interpretable policies.
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APPENDIX
A Theoretical Results for Direct Policy Learning
In this section we provide a self-contained proof of the consistency of our chosen loss func-
tion, which is known as the multinomial deviance loss Huang et al. (2019) in the literature
on multi-category cost-sensitive classification with convex surrogates. First, we note the
following fact
Proposition 2. The function Er|xL˜(f, x, r) is convex in f for non-negative rewards r
Proof. The expectation Er|x preserves convexity, so we just need to confirm that L˜(f, x, r)
is convex in f , which we can do so by rewriting as
L˜(f, x, r) =
∑
a∈A
r(a)
[(
log
∑
a′
exp fa′(x)
)
− fa(x)
]
(8)
The inner term is a convex function of f because it is a non-negative sum of convex functions
of f , namely log-sum-exp and −f . The outer sum is a non-negative sum, since the rewards
are specified to be non-negative, which preserves convexity.
Proposition 3. For non-negative rewards r, and for an f∗ that satisfies f∗ = inff Ex,rL˜(f, x, r),
the corresponding policy pi∗(x) = arg maxa f∗a (x) is equivalent to the the Bayes-optimal pol-
icy pi∗(x) = arg maxa E[r(a)|X]
Proof. First, we can write this as
inf
f
Ex,rL˜(f, x, r) = Ex inf
f(x)
Er|xL˜(f, x, r)
Because Er|xL˜(f, x, r) is convex in f (see Proposition 2), we just need to find a critical
point where ∂∂fa∗
L˜(f(x), x, r) = 0, ∀a∗ ∈ A. We can see that
∂
∂fa∗
Er|xL˜(f, x, r)
= − ∂
∂fa∗
∑
a∈A
E[r(a)|X] log exp fa(x)∑
a′ exp fa′(x)
= − ∂
∂fa∗
E[r(a∗)|X] log exp fa∗(x)∑
a′ exp fa′(x)
− ∂
∂fa∗
∑
a6=a∗
E[r(a)|X] log exp fa(x)∑
a′ exp fa′(x)
= −E[r(a∗)|X]
[
1− exp fa∗∑
exp fa′
]
+
∑
a6=a∗
E[r(a)|X] exp fa∗∑
a′ exp fa′
= −E[r(a∗)|X] + exp fa∗(x)∑
a′ exp fa′(x)
∑
a
E[r(a)|X] = 0
=⇒ E[r(a
∗)|X]∑
a E[r(a)|X]
=
exp fa∗(x)∑
a′ exp fa′(x)
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From this, we can see that
arg max
a∈A
E[r(a)|X] = arg max
a∈A
E[r(a)|X]∑
a′ E[ra′ |X]
= arg max
a∈A
exp fa∑
a′ exp fa′
= arg max
a∈A
log
(
exp fa∑
a′ exp fa′
)
= pi∗(x)
Completing the proof that at optimality, the optimal
f∗ = arg inf
f(x)
Er|xL˜(f, x, r)
yields a calibrated decision rule pi∗(x)
We make two minor remarks: First, as a practical matter, we drop the usual constraint
(used to ensure uniqueness) that
∑
a fa(x) = 0, as we impose `2 regularization on the
weights of our fa(x) = θ
T
a x functions in our experiments. Second, this formulation requires
that the reward vector r is non-negative, but this can be relaxed in a straightforward way
by replacing r(a) with maxa′ r(a
′) − r(a) in the below. We tried this latter formulation in
our experiments and it did not have a significant impact on results.
B Dataset
B.1 Feature Details
In this section, we provide additional details about the construction of a few features used
in the models.
Lab Values. For a given lab test and backward window, the corresponding feature value
is the mean result of all results for that lab value within the specified time window. The
dataset contains lab results for white blood counts (WBC), absolute neutrophil counts
(ANC), absolute lymphocyte counts (ALC), and CD4/CD8 counts.
Colonization pressure. Colonization pressure is defined as the proportion of resistant
specimens to a given antibiotic across a specified location and time window. We calculate
the colonization pressure for 25 different antibiotics in the window from 7 days prior to 90
days prior to the specimen collection date among all patients with UTIs. We calculate col-
onization pressure values at 3 different location hierarchies: (1) the ward/clinic of specimen
collection, (2) the hospital of collection, and (3) across the entire dataset.
C Experiments
This section contains details about the experiments conducted in this paper. Code will
be made available in the future, and more specific information (e.g, exact hyperparameter
settings used for tuning) can be found there.
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C.1 Thresholding
We use sklearn’s logistic regression implementation to train models for predicting resistance
to each of the four antibiotic treatments. Hyperparameters are tuned using validation on
the cohort of patients from 2012-13.
Our threshold search space is defined implicitly by a fixed set of 9 false negative rates
as follows: for each FNR value and antibiotic, the corresponding probability threshold is
the one that achieves that FNR rate among the training set resistance predictions for that
drug. Since there is a strong correlation between resistance to CIP and LVX, we constrain
T to combinations where thresholds for CIP and LVX are the same. Our threshold space
T consists of 93 = 729 possible combinations.
When a threshold combination results in predictions of resistance for all antibiotic treat-
ments, the policy falls back on a default 1st-line antibiotic. We chose to always default to
recommending NIT, as it has a significantly lower overall resistance rate than SXT in the
training set.
In Figure 1, we show the results of optimal policies pij for budget constraint values bj in
[0.01, 0.05] (in increments of 0.01) and (0.05, 1.0] (in increments of 0.05).
C.2 Expected Reward Maximization
We follow the same procedure for training logistic regression models as described for the
thresholding approach. The indirect learning policy frontier in Figure 1 contains the per-
formance of models learned using values of ω in the range [0.85, 1] (in increments of 0.005).
C.3 Direct Learning
Models are trained using an Adam optimizer with a learning rate of 10−4 and L2 regu-
larization with penalty 10−3, and are trained for 15 epochs. Models were implemented in
PyTorch. The policy frontier in Figure 1 contains the performance of models learned using
values of ω in the range [0.85, 1] at increments of 0.005. We plot the mean IAT and 2nd
line usage outcomes for each setting of ω from policy learning across 30 trials.
The direct learning model with the deferral action was trained using the same learning
rate and regularization hyperparameters. The values for λdefer were selected from the range
[0, 0.05] (in increments of 0.0025). Mean deferral rates and IAT / 2nd line usage rates shown
in Figure 2 were calculated over 30 trials for each setting of λdefer.
C.4 Synthetic Experiments
Our synthetic environment consists of a 10-dimensional feature space and an action space A
with 3 actions. Each feature value is drawn i.i.d. from a standard normal distribution. The
feature coefficient values (i.e, αi, βi) are selected manually to ensure that the mean outcomes
for each action in the dataset are roughly 0.5. All these coefficients have magnitude larger
than 1, to ensure that learning approximations to these values is necessary for learning a
good predictive model.
In the indirect approach, we train logistic regression models to predict treatment out-
comes for each action. We use the saga solver in sklearn’s logistic regression implemen-
tation to train models. Hyperparameters - L1 vs. L2 regularization and regularization
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strength - are tuned using 10-fold cross validation on the training set. Models are trained
for a maximum of 100 iterations.
In the direct approach, the convex surrogate loss is optimized using SGD with a learning
rate of 0.1 and L2 regularization with λ = 0.001. Models are trained for 50 epochs. This
model was implemented using PyTorch.
Figure 3 shows the outcomes of indirect and direct policy learning using training sets of
various sizes on a fixed test set of 106 samples drawn from the specified generative model.
We only evaluate outcomes on samples where there was at least one ineffective and one
effective treatment (i.e, not all 0 or 1 outcomes), as these are the only examples where the
policy’s decision can affect the outcome. We train both indirect and direct approaches on
the same 10 randomly drawn training sets for each sample size, and plot the mean outcome
and standard deviations for each setting across these samples in Figure 3.
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